Recent News for PTGX - Protagonist Therapeutics, Inc.

Date Title
Oct 2 The Protagonist Therapeutics (NASDAQ:PTGX) Share Price Is Down 45% So Some Shareholders Are Getting Worried
Oct 1 Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting
Sep 25 Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2
Sep 10 The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris
Sep 4 Protagonist Therapeutics Reports Granting of Inducement Awards
Sep 3 Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference
Aug 27 Does Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Salary Reflect Performance?
Aug 7 Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
Aug 7 Protagonist EPS misses by $0.79
Aug 7 Protagonist Therapeutics Reports Second Quarter 2019 Financial Results
Aug 1 Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
Jul 30 Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Jul 16 Protagonist Therapeutics Reports Granting of Inducement Award
Jul 11 Should You Be Worried About Insider Transactions At Protagonist Therapeutics, Inc. (NASDAQ:PTGX)?
Jul 8 Benzinga's Top Upgrades, Downgrades For July 8, 2019
Jul 8 Canaccord likes Rhythm Pharma in premarket analyst action
Jun 23 Here’s What Hedge Funds Think About Protagonist Therapeutics, Inc. (PTGX)
Jun 17 Protagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare Conference
May 29 New finance chief at Protagonist
May 29 Protagonist Therapeutics Appoints Don Kalkofen as Chief Financial Officer
May 15 Protagonist Therapeutics, Inc. Common Stock (PTGX) Q1 2019 Earnings Call Transcript
May 14 Protagonist IBD candidate shows positive action in early-stage study; shares up 2%
May 14 Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study
May 9 What Protagonist Doesn't Want You To See
May 9 Sarepta a "Fresh Pick" at Baird in premarket analyst action
Back to the Main PTGX Page...